


The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Testosterone derivatives of general A~~ testosterone compound of formula I



in which

- R^6 ~~represents is~~ represents is a hydrogen atom, a hydroxy group, a C_1 - C_{10} alkoxy group, a C_1 - C_{10} alkanoyloxy group or a halogen atom,
- R^{15} and R^{16} each are a hydrogen atom or together form a bond,
- R^{17a} ~~represents is~~ represents is a C_1 - C_4 alkyl group, a C_2 - C_4 alkynyl group, or a radical of formula Formula $C_nF_mH_o$, ~~whereby wherein~~ whereby wherein $n = 1, 2, 3$ or 4 , $m > 1$ and $m+o=2n+1$,
- R^{17b} is a hydroxy group, a C_1 - C_{10} alkoxy group or a C_1 - C_{10} alkanoyloxy group,
- A is an unbranched C_6 - C_{13} alkylene group,
- B ~~represents is~~ represents is an oxygen atom, a grouping $-S(O)_p$ group, ~~whereby wherein~~ whereby wherein $p = 0, 1$ or 2 , an iminocarbonyl group $-C(O)N(Y)-$, an imino group $-N(Y)-$, a carbonylimino group $-N(Y)C(O)-$, a sulfonylimino group $-N(Y)S(O)_2-$, ~~whereby wherein~~ whereby wherein Y is a hydrogen atom or a C_1 - C_8 alkyl group, a sulfonyloxy group $-OS(O)_2-$, a dimethylsilyloxy group $-O-Si(CH_3)_2-$ or a carbonylsulfanyl group $-SC(O)-$, or B ~~represents is~~ represents is a bond between A and C, or together with C forms a bond between A and D,

C ~~represents~~ is a bond between B and D, or together with B forms a bond between A and D, or an unbranched C₁-C₆ alkylene group, a phenylene group, a substituted phenylene group, a five-ring or six-ring heteroarylene group, a substituted five-ring or six-ring heteroarylene group, or a five-ring or six-ring heteroarylene group that is condensed with a phenyl ring,

and

D ~~represents~~ is a hydrogen atom, a C₁-C₄ alkyl group, a vinyl group, a C₁-C₄ alkoxy group, a C₁-C₄ alkoxy carbonyl group, a bis(C₁-C₄ alkoxy carbonyl)methyl group, an acetyl(C₁-C₄ alkoxy carbonyl)methyl group, a cyano group, a carboxy group, an azide group, a hydroxy group, a halogen atom or a radical of formula C_nF_mH_o, ~~whereby~~ wherein n = 1, 2, 3 or 4, m > 1 and m+o=2n+1.

C1 cont.
2. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, characterized in that wherein R^{17a} ~~represents the~~ is a methyl group, the an ethyl group, the a trifluoromethyl group or the a pentafluoroethyl group.

3. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, wherein R^{17b} is the a hydroxy group, a C₁-C₅ alkoxy group or a C₁-C₃ alkanoyloxy group.

4. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 3, wherein R^{17b} is the a hydroxy, methoxy, ethoxy or acetyloxy group.

5. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, wherein R⁶ ~~represents~~ is a hydrogen atom, the a hydroxy group or a halogen atom.

6. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, wherein R¹⁵ and R¹⁶ each represent a hydrogen atom.

7. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to

claim 1, wherein radical ABCD ~~means~~ is 9-hydroxynonyl, 7-(acetylsulfanyl)heptyl or 7-(4-cyanobutoxy)heptyl.

8. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, wherein the five-ring- or six-ring-heteroaromatic compound ~~compounds~~ of radical C are ~~is~~ pyrrole, thiophene, imidazole, thiazole, oxazole, triazole, thiadiazole, indole, benzoxazole, benzothiazole, pyridine, or pyrimidine.

9. (Currently Amended) ~~Testosterone derivatives~~ A testosterone compound according to claim 1, ~~wherein they represent the following compounds:~~ that is

C1 cont.

7 α -(9-Chlorononyl)-17 α -methyl-3-oxoandrost-4-en-17 β -yl-acetate,
7 α -(9-Chlorononyl)-17 β -hydroxy-17 α -methylandrost-4-en-3-one,
17 β -Hydroxy-7 α -(9-iodononyl)-17 α -methylandrost-4-en-3-one,
17 β -Hydroxy-7 α -(9-hydroxynonyl)-17 α -methylandrost-4-en-3-one,
7 α -(10-Chlorodecyl)-17 β -hydroxy-17 α -methylandrost-4-en-3-one,
17 β -Hydroxy-7 α -(11-hydroxyundecyl)-17 α -methylandrost-4-en-3-one,
7 α -(11-Bromoundecyl)-17 β -hydroxy-17 α -methylandrost-4-en-3-one,
17 β -Hydroxy-17 α -methyl-7 α -[7-(phenylsulfanyl)heptyl]androst-4-en-3-one,
17 β -Hydroxy-17 α -methyl-7 α -[9-[(4,4,5,5,5-pentafluoropentyl)sulfanyl]nonyl]androst-4-en-3-one,
17 β -Hydroxy-17 α -methyl-7 α -[9-(phenylsulfanyl)nonyl]androst-4-en-3-one,
7 α -[9-[(5-Chloropentyl)sulfanyl]nonyl]-17 β -hydroxy-17 α -methylandrost-4-en-3-one,
17 β -Hydroxy-7 α -[9-[(5-hydroxypentyl)sulfanyl]nonyl]-17 α -methylandrost-4-en-3-one,
7 α -(9-Azidononyl)-17 β -hydroxy-17 α -methylandrost-4-en-3-one,
7 α -[7-(Acetylsulfanyl)heptyl]-17 β -hydroxy-17 α -methylandrost-4-en-3-one,
17 β -Hydroxy-17 α -methyl-7 α -[7-[(4,4,5,5,5-pentafluoropentyl)sulfanyl]heptyl]androst-4-en-3-one,
N-[7-(17 β -Hydroxy-17 α -methyl-3-oxoandrost-4-en-7 α -yl)heptyl]pentanamide,
17 β -Hydroxy-17 α -methyl-3-oxoandrost-4-en-7 α -octane nitrile,
5-[[7-(17 β -Hydroxy-17 α -methyl-3-oxoandrost-4-en-7 α -yl)heptyl]oxy]pentanenitrile,

17 β -Hydroxy-17 α -methyl-7 α -[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]androst-4-en-3-one,

N-[9-(17 β -Hydroxy-17 α -methyl-3-oxoandrost-4-en-7 α -yl)nonyl]methanesulfonamide, or
7 α -(9-Chlorononyl)-6 β -hydroxy-17 α -methyl-3-oxoandrost-4-en-17 β -yl-acetate.

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

*C1
cancel*
13. (Currently Amended) ~~Pharmaceutical agents~~ A pharmaceutical composition that
~~contain~~ comprising at least one testosterone ~~derivative of general compound of~~ formula I
according to claim 1 and one or more physiologically ~~compatible~~ acceptable adjuvants and/or
vehicles ~~that are commonly used in galenicals.~~

14. (New) A method for the long-term antiandrogen therapy of an androgen-dependent disease comprising administering to a patient in need thereof a pharmaceutical composition in accord with claim 13.

15. (New) A method according to claim 14, wherein the androgen-dependent disease is prostate cancer.

16. (New) A method for the long-term antiandrogen therapy of prostate cancer comprising administering to a patient in need thereof a pharmaceutical composition comprising at least one testosterone compound of formula I according to claim 9 and one or more physiologically acceptable adjuvants and/or vehicles.

17. (New) A method for the long-term antiandrogen therapy of prostate cancer comprising administering to a patient in need thereof a pharmaceutical composition comprising

17 β -Hydroxy-7 α -(9-hydroxynonyl)-17 α -methylandrost-4-en-3-one, 7 α -[7-(Acetylsulfanyl)heptyl]-17 β -hydroxy-17 α -methylandrost-4-en-3-one, or 5-[[7-(17 β -Hydroxy-17 α -methyl-3-oxoandrost-4-en-7 α -yl)heptyl]oxy]pentanenitrile according to claim 9 and one or more physiologically acceptable adjuvants and/or vehicles.